Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad
More articles/Ad
More articles
-
European banks are steering well clear of new issue markets during the coronavirus pandemic, avoiding having to call on investors for funding by taking advantage of attractive central bank funding schemes. -
The World Bank has increased its funding allowance for its 2019-20 fiscal year by $5bn. It now plans to raise between $55bn and $65bn, up from its previous $55bn-$60bn target, according to a funding official at the supranational.
-
Airbus, the European aerospace company, has signed a new €15bn credit facility as it looks to ride out effects of the Covid-19 pandemic upon its sector. The company is ramping up liquidity on the assumption it will not have access to capital markets.
-
The top officials at various Chinese regulatory bodies made efforts over the weekend to calm nerves on default risks and fleeing foreign capital as they tame the spread of the Covid-19 coronavirus within the country.
-
The Nordic region’s credit markets are experiencing something of a lockdown as the spread of Covid-19 lead to dozens of fund providers halting withdrawals last week and the effective closure of the primary market due to a shortage of liquidity.
-
Chinese biotechnology company InnoCare Pharma’s shares surged over 10% on their Monday debut, following an online opening ceremony for the HK$2.2bn ($288.7m) listing in Hong Kong.
